Rémi Constanze, Gerlach Christina
Klinik und Poliklinik für Palliativmedizin, Arzneimittelinformation, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland.
Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, Knochenmarktransplantation mit Abteilung für Pneumologie), Bereich Palliativmedizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
Schmerz. 2021 Feb;35(1):61-73. doi: 10.1007/s00482-020-00522-5. Epub 2021 Jan 14.
Palliative care serves to improve the quality of life in patients suffering from incurable diseases. Pharmacotherapy of distressing symptoms plays an important role. Off-label use refers to the use of drugs outside the marketing authorization. In addition to the indications off-label use may also be due to duration of treatment, route of administration and the admixture of substances. Off-label use is common in palliative and hospice care and is probably unavoidable in many cases. For treatment planning and realization of off-label therapy in clinical practice, patient-related aspects, information, therapy monitoring and documentation of therapy effects should be considered in addition to drug-related information. Only in this way it is possible to offer a scientifically adequate, appropriate and economic therapy that is linked to an appropriate risk-benefit ratio for the individual patient. Due to the lack of authorization studies, reporting is of particular importance.
姑息治疗旨在提高患有不治之症患者的生活质量。对令人痛苦的症状进行药物治疗起着重要作用。超说明书用药是指在药品上市许可范围之外使用药物。除了适应证外，超说明书用药还可能由于治疗持续时间、给药途径和物质混合等原因。超说明书用药在姑息治疗和临终关怀中很常见，在许多情况下可能是不可避免的。在临床实践中进行超说明书治疗的规划和实施时，除了与药物相关的信息外，还应考虑与患者相关的方面、信息、治疗监测以及治疗效果的记录。只有这样，才有可能提供一种科学合理、适当且经济的治疗方法，并为个体患者提供合适的风险效益比。由于缺乏授权研究，报告尤为重要。
